Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
AGC, antitumor, ATM, Brisbane, Bulletin, burden, CA, central, chemotherapeutic, concomitantly, CrossMAb, cyber, cybersecurity, Daiichi, DCR, dual, DutaFab, Eric, ESPP, exhausted, flat, fourth, futility, GEJ, GMP, Hoffman, Incyte, Jay, marginal, Median, MLF, morphologic, moved, mutational, offshore, ORR, payroll, PCAOB, platelet, provisional, quantifying, remission, repatriated, revalued, Risser, SAB, Sankyo, shelf, Siegel, software, store, stored, survival, taxation, theft, unclear, unconfirmed, versatility
Filing tables
Filing exhibits
Related press release
Associated MGNX transcripts
MGNX similar filings
Filing view
External links
EXHIBIT 32.1
Certification of Principal Executive Officer Pursuant to 18 U.S.C. 1350 (Section 906 of the Sarbanes-Oxley Act of 2002)
I, Scott Koenig, President and Chief Executive Officer (principal executive officer) of MacroGenics, Inc. (the “Registrant”), certify, to the best of my knowledge, based upon a review of the Annual Report on Form 10-K for the period ended December 31, 2017 of the Registrant (the “Report”), that:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant. |
/s/ Scott Koenig
Name: Scott Koenig, M.D., Ph.D.
Date: February 27, 2018